From biomarker to targeted therapy: investigating trophoblast cell-surface antigen 2 expression in triple-negative breast cancer– insights from the national cancer institute
- Published on 06/10/2025
- Reading time: 5 min.
Ebrahim Noura A. A. 1, Hussein Mustafa A. 1, Sobeih Mohamed Emam 2, Amin Nancy H. 1
1 https://ror.org/03q21mh05 Oncologic Pathology Department National Cancer Institute (NCI) - Cairo University Giza Egypt
2 https://ror.org/03q21mh05 Medical Oncology Department National Cancer Institute (NCI) - Cairo University Giza Egypt
Abstract
Background Triple-negative breast cancer (TNBC) is characterized by its aggressive behavior and limited treatment options, primarily due to the lack of expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). TROP-2, a transmembrane glycoprotein, exhibits notable overexpression in a spectrum of highly aggressive cancers including pancreatic, gastric, and ovarian cancers. This overexpression has established...
To continue reading this article in Full-Text...
Peer-Reviewed Journals A-Z
Search | Advanced search
Get the latest news in Oncology
Receive our newsletter to stay up to date with the latest news in Oncology
